ACS Omega · 2024 · 15 citations · 66 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryTheranosticsClinical Translation Of TheranosticsLead Compound DesignLigand BindingNanomedicineNanoparticle DesignTheranostic ApproachesFluorescent Lipid AnalogsFluorescent Probe DesignFluorophore DesignSmall-molecule TheranosticsTheranostic AgentsTheranostic Drug DeliveryTheranostic NanomedicineTheranostic Platforms
. With this Review, we intend to provide a milestone in the acquired knowledge in the field of AD theranostics, encouraging the future development of properly designed theranostic compounds with improved chances to reach clinical applications.
66
Lecanemab in Early Alzheimer’s Disease
Christopher H. van Dyck, Chad J. Swanson, Paul Aisen et al. · New England Journal of Medicine · 2022 · 5.2K citations · Full text
The Lancet · 2021 · 4.9K citations · Full text
Life Sciences, Genetics, Neurology +17
2018 Alzheimer's disease facts and figures
Alzheimer s & Dementia · 2018 · 1.9K citations
Inorganic Nanoparticles for MRI Contrast Agents
Hyon Bin Na, In Chan Song, Taeghwan Hyeon · Advanced Materials · 2009 · 1.8K citations
Donanemab in Early Alzheimer’s Disease
Mark A. Mintun, Albert Lo, Cynthia Evans et al. · New England Journal of Medicine · 2021 · 1.7K citations · Full text